Navigation Links
Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
Date:10/1/2009

e treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. Catalyst has also recently been granted worldwide rights to another patented drug by Northwestern University. The Company intends to pursue development of this drug for several indications, including stimulant addiction and epilepsy. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including those described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

SOURCE Catalyst Pharmaceutical Partners, Inc.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015  Regulatory ... and government, where regulations are often strict and ... is driving a demand for professionals who have ... these regulations across a product lifecycle and demonstrate ... The University of California, Irvine Extension , ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
(Date:8/31/2015)... MOUNTAIN VIEW, Calif. , Aug. 31, ... EURONEXT: SAN) and the life sciences team at Google ... and outcomes for people with type 1 and type ... and devices with Google,s expertise in analytics, miniaturized electronics ... how to improve diabetes care by developing new tools ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric Disease and ... emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author Dr Theodore ... largely untreatable - with mostly palliative treatments only - and now we have ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Since 1946, ... patient-oriented dental care. From the moment a patient arrives at the office, the ... Tuckman will work with each and every patient to create a complete dental treatment ...
(Date:8/31/2015)... Aliso Viejo, CA (PRWEB) , ... August 31, 2015 , ... With the FCPX LUT ... to footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... table. This pack comes with 60 soft CUBE LUT files. , FCPX LUT Soft requires ...
(Date:8/31/2015)... ... 31, 2015 , ... According to an article published August 3rd ... adolescents who underwent bariatric surgery “felt significantly better two years after surgery.” The article ... in the study felt that their “mental health had been normalized” at the point ...
(Date:8/31/2015)... ... 31, 2015 , ... The dental implant and prosthetic market in the U.S. ... Dentistry. (See Press Room ) More than 30 million Americans are missing all ... increasing demand for dental implants, the National Association of Dental Laboratories (NADL) created the ...
Breaking Medicine News(10 mins):Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 2Health News:Article on Adolescent Bariatric Surgery Demonstrates the Powerful Effect of Being in Control, Notes Dr. Michael Feiz 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4
... PRA International, a leading Clinical Research Organization, announces ... Sao Paulo, Brazil office. Drug Safety Centers are a ... They are staffed with drug safety professionals who are ... management. Furthermore, our drug safety personnel support our ...
... Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging ... world,s first permanent tattoo ink designed to be both ... a June 1st article in Time Magazine. The ... Infinitink, a product developed to address tattoo regret and ...
... FOR ORAL MUCOSITIS , DALLAS, May 27 ... (OTC Bulletin Board: ACCP) , ( http://www.accesspharma.com ... MuGard(TM) , its proprietary oral mucositis ... Nordic countries by its European commercial partner, SpePharm ...
... study finds, , , , WEDNESDAY, May 27 (HealthDay News) ... been identified by U.S. researchers, who said their finding ... The researchers, from the Washington University School of Medicine ... ATR gene in tumors boosts the risk of cancer ...
... a privately held international health care consulting group, announced ... The Sage Group to include, in addition to the ... for Chronic Fatigue Syndrome *, additional partnering efforts ... preventative pandemic flu vaccines and the additional role of ...
... Millennium Research Group,s new European dental implant report now ... 27 Millennium Research Group,s (MRG,s) new European ... despite unfavorable economic conditions, the market was valued at ... over $2.7 billion by 2013 as new technologies drive ...
Cached Medicine News:Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 2Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 3Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 2Health News:Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex 3Health News:Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM) 2Health News:Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM) 3Health News:Gene Mutation May Up Risks of Endometrial Cancer 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 3Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 4Health News:Increasingly Competitive European Dental Implant Market to Reach Over $2.7 Billion by 2013 Despite Unfavorable Economic Conditions 2Health News:Increasingly Competitive European Dental Implant Market to Reach Over $2.7 Billion by 2013 Despite Unfavorable Economic Conditions 3
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
... With a zoom ratio of ... 0.75X to 11.25X, and the ... intervals from 1X to 11X, ... Magnifications of 3.75X to 540X ...
Inquire...
Fluar objectives have been designed especially for qualitative and quantitative analyses of ion movements and for particularly critical fluorescence methods (e.g. chromosome studies in human and cyto...
Medicine Products: